Dr. Saks, a board-certified oncologist, has more than 25 years of experience developing specialty pharmaceutical products. He was the founding CEO of Jazz Pharmaceuticals from 2003 until his retirement in 2009. From 2001 until he joined Jazz, Dr. Saks was company group chairman of ALZA Corporation and member of the Johnson & Johnson Pharmaceutical Operating Committee. From 1992 until 2001, he held executive positions at ALZA, including Senior Vice President of Medical Affairs and Group Vice President, where he was responsible for clinical, regulatory and commercial activities. Prior to joining ALZA, Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. From 1987 to 2000, Dr. Saks was Assistant Clinical Professor of Medicine in the oncology division of the Department of Medicine at the University of California, San Francisco. He has served as a Director for many public biopharma companies, including Ribozyme, Coulter, Corixa, Jazz Pharma, Ilypsa, Trubion, Cougar, and Auspex.
Dr. Saks has a Bachelor’s degree in biology and his medical degree from the University of Illinois. He completed his residency in internal medicine at Texas Southwestern, and his fellowship in oncology at the University of California – San Francisco, and is Board certified in both specialties. Dr. Saks is also a Director for Depomed, Tonix Pharmaceuticals, NuMedii, and Velocity Pharmaceutical Development.